The ASCO 2019 Meeting is just around the corner and we’re excited to bring our Sample to Insight solutions to Chicago on May 31st – June 4th. We hope to see you there!
Cancer is the epitome of personalized medicine, with diagnosis, prognosis and therapeutic success underpinned by our understanding of the variants specific to each patient. Treatments should reflect this individuality but developing the right tests and accessing the rapidly growing clinical-datasets to guide personalized therapeutic decisions can be challenging.
What if there were a key partner to help you deliver on personalized oncology care for every patient? A partner with the expertise to help you develop state of the art Sample to Insight molecular tests, and to maximize insights generated to inform your future test development? At QIAGEN we pride ourselves in developing and commercializing the best in class oncology diagnostics to expand the treatment options for clinicians. With a decade of experience in delivering CDx solutions, we boast a strong track record of on-time and on-spec development, as well as global test availability from day-one of drug approval. We are committed to supporting our customers along the complete drug discovery pipeline.
Whether you need a solution to support evidence-guided biomarker discovery, a CDx for your breakthrough therapy, or help implementing interpretation guidelines, we have products and expertise to meet your needs. From PCR to NGS, expert-powered clinical interpretation or custom-designed test, we can help you deliver personalized diagnostics for real-world impact.
Explore our solutions and speak with our experts in booth 24103. Interested in receiving a demo of one of our Sample to Insight offerings? Why not sign up in advance to book a demo with one of our team.